Funds

HELIUM ALPHA - S

28/03/2025
Synthetic risk indicator
Net asset value43.19
Performance MTD0 %
Performance YTD0 %
AuM of the fund1 Mios
AuM of the share class4.3 k

Launched in September 2017, the Helium Alpha fund relies on a quantitative equity long/short hybrid strategy, also called Quantamental which combines quantitative and fundamental portfolio management approaches.

Invested in Europe, Helium Alpha is an absolute performance fund moderately correlated with the equity markets.

session3 years5 years10 yearsLaunch
Accumulated Performance-2.4%2.9%9.8%-8%
Annualized Performance-2.4%1%1.9%-1%
% positive months41.7%44.4%51.7%-51.6%
Perf. Monthly Average-0.2%0.1%0.2%-0.1%
Annualized Volatility4.3%4.8%5%-5.7%
Sharpe Ratio-1.3-0.30.1-0.1
Drawdown Max-5.1%-5.1%-6.5%--11%
Created with Highcharts 7.2.0EUR201820192020202120222023202420259009501000105011001150
ESTR
NAV HA.PartS

This is a marketing communication. Past performance is no guarantee of future performance. The investment presents a risk of capital loss. Before any investment, please refer to the risks and various costs of each share class available in the prospectus and the KIDs.

Performances since inception in %

JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecemberYtd Perf%
2025-0.18%-2.00%-0.89%-3.04%
2024-0.52%0.87%2.85%-0.66%0.73%0.38%-1.00%1.14%0.32%0.00%-0.82%0.66%3.95%
2023-1.80%-1.51%0.81%-0.12%-0.34%1.00%-0.81%-0.14%-0.53%2.54%-0.87%0.27%-1.55%
2022-1.50%0.39%2.21%-0.68%-1.08%1.99%1.09%0.99%0.09%0.94%-0.43%0.00%4.00%
20211.29%0.85%3.23%1.72%2.39%-0.87%1.66%-1.33%1.77%0.08%-0.48%1.51%12.36%
20201.35%-0.96%-1.14%0.97%0.31%-0.61%0.66%-1.27%0.12%-1.44%-1.79%-1.25%-4.99%
20192.37%1.44%0.46%-1.61%0.21%-0.06%0.08%-0.59%-0.55%-0.46%1.37%-1.07%1.53%
20180.86%-1.55%-0.30%1.14%0.15%-1.71%0.30%0.24%0.10%-2.15%-3.05%-0.48%-6.35%
20170.59%0.97%-0.34%1.83%3.08%

This is a marketing communication. Past performance is no guarantee of future performance. The investment presents a risk of capital loss. Before any investment, please refer to the risks and various costs of each share class available in the prospectus and the KIDs.

Information elements

Inception 22/09/2017
Legal status SICAV - UCITS
Volatility target 5% - 7%
Recommended investment period 5 years
Liquidity / NAV Weekly
Deadline Thursday before 5 pm CET
Senior Manager Olivier Leymarie
Code ISIN LU1685859263
Code Bloomberg HEALSEC LX
SFDR Article 8
Base currency EUR
Domicile Luxembourg
Administrator CACEIS Bank Luxembourg
Auditor Deloitte & Touche
Minimum initial subscription EUR 100 000
Management fees 1.00%
Performance fees 15% High Water Mark
Hurdle ESTR
Assignment result Capitalization

INVESTOR RELATIONS

Carl Dunning-Gribble
Head of sales and marketing
T: +331 42 56 56 28

Lindren Thanacoody
Investors Relations
T: +331 42 56 56 26

Christina Perri
Investors Relations
T: +331 42 56 93 19

Bastien Perrin
Investors Relations
T: +331 42 56 93 15

Julien Vanlerberghe, CFA
Investors Relations
T: +331 42 56 56 32